NASDAQ:JUNO - 1877 Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00 %
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$86.96 As of 03/6/2018 01:00 AM ET

+0.30 (1.20%)

Get New 1877 Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for JUNO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JUNO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for 1877 in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $86.96.

N/A

The current consensus among 0 polled investment analysts is to n/a stock in 1877. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/23/2019

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/21/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/21/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/19/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/17/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/15/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/16/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/16/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/24/2018	Standpoint Research	Reiterated Rating	Buy ➝ Hold		Low	i
1/24/2018	Barclays	Downgrade	Overweight ➝ Equal Weight	$55.00 ➝ $87.00	Low	i
1/23/2018	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$56.00 ➝ $87.00	Low	i
1/23/2018	Raymond James	Downgrade	Outperform ➝ Hold		Low	i Rating by Reni Benjamin at Raymond James
1/22/2018	SunTrust Banks	Reiterated Rating	Buy ➝ Hold		Low	i
1/22/2018	Needham & Company LLC	Downgrade	Buy ➝ Hold		Low	i
1/22/2018	Guggenheim	Downgrade	Buy ➝ Neutral		Low	i
1/17/2018	Raymond James	Reiterated Rating	Outperform ➝ Buy		High	i Rating by Reni Benjamin at Raymond James
1/17/2018	Citigroup	Downgrade	Buy ➝ Neutral		High	i
1/17/2018	Wedbush	Downgrade	Outperform ➝ Neutral		High	i Rating by D. Nierengarten at Wedbush
1/17/2018	Wells Fargo & Company	Reiterated Rating	Market Perform	$54.00 ➝ $63.00	High	i
1/11/2018	Raymond James	Reiterated Rating	Buy		Medium	i Rating by Reni Benjamin at Raymond James
1/11/2018	JPMorgan Chase & Co.	Reiterated Rating	Hold		High	i
1/5/2018	Needham & Company LLC	Initiated Coverage	Buy ➝ Buy	$65.00	Medium	i
12/13/2017	Maxim Group	Set Price Target	Buy	$56.00	High	i Rating by Jason McCarthy at Maxim Group
12/12/2017	Wells Fargo & Company	Downgrade	Outperform ➝ Market Perform		High	i
12/11/2017	Raymond James	Reiterated Rating	Buy		High	i Rating by Reni Benjamin at Raymond James
11/3/2017	Raymond James	Boost Price Target	Outperform	$45.00 ➝ $61.00	N/A	i Rating by Reni Benjamin at Raymond James
11/3/2017	Cowen	Reiterated Rating	Buy		N/A	i
11/2/2017	Maxim Group	Reiterated Rating	Buy	$56.00	N/A	i
11/2/2017	SVB Leerink	Reiterated Rating	Outperform ➝ In-Line	$34.00 ➝ $56.00	N/A	i
11/2/2017	Wedbush	Reiterated Rating	Outperform	$42.00 ➝ $64.00	N/A	i Rating by D. Nierengarten at Wedbush
11/2/2017	SunTrust Banks	Upgrade	Hold ➝ Buy		N/A	i
10/31/2017	Citigroup	Reiterated Rating	Buy	$59.00	N/A	i
10/27/2017	Cowen	Reiterated Rating	Buy	$49.00	N/A	i
10/9/2017	Maxim Group	Reiterated Rating	Buy ➝ Buy	$34.00 ➝ $56.00	N/A	i
10/6/2017	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$44.00	N/A	i
10/6/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$27.00 ➝ $43.00	N/A	i
9/6/2017	Barclays	Initiated Coverage	Overweight	$55.00	Medium	i
9/5/2017	Wells Fargo & Company	Reiterated Rating	Outperform ➝ Outperform	$35.00 ➝ $54.00	Low	i
8/31/2017	Standpoint Research	Reiterated Rating	Buy ➝ Reduce		Medium	i
8/29/2017	Raymond James	Upgrade	Market Perform ➝ Outperform	$45.00	High	i Rating by Reni Benjamin at Raymond James
8/29/2017	Wedbush	Upgrade	Neutral ➝ Outperform	$42.00 ➝ $42.00	High	i Rating by D. Nierengarten at Wedbush
8/28/2017	BTIG Research	Upgrade	Sell ➝ Neutral		High	i
8/7/2017	Morgan Stanley	Boost Price Target	Equal ➝ Equal Weight	$26.00 ➝ $27.00	Low	i
6/20/2017	SVB Leerink	Reiterated Rating	Outperform	$34.00	Low	i
6/12/2017	SVB Leerink	Reiterated Rating	Outperform		Low	i
6/8/2017	BTIG Research	Downgrade	Neutral ➝ Sell	$22.60 ➝ $23.73	Low	i
6/6/2017	Wedbush	Reiterated Rating	Neutral	$24.00	Medium	i
6/6/2017	BTIG Research	Downgrade	Neutral ➝ Sell	$12.00 ➝ $23.00	Medium	i
5/18/2017	(FBRC)	Reiterated Rating	Hold		Medium	i Rating by Edward White at (FBRC)
5/15/2017	Wedbush	Reiterated Rating	Neutral	$24.00	N/A	i
5/8/2017	Morgan Stanley	Lower Price Target	Equal Weight	$27.00 ➝ $26.00	High	i
5/5/2017	Wedbush	Reiterated Rating	Neutral	$24.00	High	i
5/5/2017	(FBRC)	Lower Price Target	Mkt Perform ➝ Mkt Perform	$30.00 ➝ $29.00	High	i Rating by Edward White at (FBRC)
4/4/2017	Citigroup	Lower Price Target	Buy	$34.00 ➝ $30.00	Low	i
3/30/2017	Cowen	Reiterated Rating	Buy	$41.00 ➝ $36.00	Low	i
3/3/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral	$34.00 ➝ $31.00	N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
3/3/2017	Wedbush	Reiterated Rating	Neutral	$24.00	N/A	i
3/2/2017	(FBRC)	Set Price Target	Hold	$30.00	N/A	i Rating by Edward White at (FBRC)
3/2/2017	Maxim Group	Set Price Target	Buy	$34.00	N/A	i Rating by Jason McCarthy at Maxim Group
2/22/2017	Wells Fargo & Company	Initiated Coverage	Outperform ➝ Outperform		N/A	i
2/1/2017	Wedbush	Initiated Coverage	Neutral	$24.00	N/A	i
1/11/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold		N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
12/6/2016	(FBRC)	Set Price Target	Hold	$30.00	N/A	i Rating by Edward White at (FBRC)
12/6/2016	Raymond James	Reiterated Rating	Outperform ➝ Market Perform		N/A	i
12/5/2016	Cowen	Reiterated Rating	Buy	$51.00	N/A	i Rating by Chris Shibutani at Cowen Inc
12/5/2016	Maxim Group	Set Price Target	Buy	$34.00	N/A	i Rating by Jason McCarthy at Maxim Group
12/1/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold	$34.00	N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
11/28/2016	SVB Leerink	Reiterated Rating	Outperform	$45.00 ➝ $34.00	N/A	i Rating by Michael Schmidt at SVB Leerink LLC
11/25/2016	SunTrust Banks	Downgrade	Buy ➝ Hold	$48.00 ➝ $25.00	N/A	i
11/24/2016	JPMorgan Chase & Co.	Set Price Target	Hold	$39.00 ➝ $34.00	N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
11/23/2016	BTIG Research	Reiterated Rating	Neutral		N/A	i
11/23/2016	Maxim Group	Lower Price Target	Buy	$50.00 ➝ $34.00	N/A	i
11/23/2016	(FBRC)	Downgrade	Outperform ➝ Market Perform	$30.00	N/A	i Rating by Edward White at (FBRC)
11/3/2016	BTIG Research	Upgrade	Sell ➝ Neutral		N/A	i
10/15/2016	(FBRC)	Reiterated Rating	Outperform	$61.00	N/A	i Rating by Edward White at (FBRC)
9/27/2016	SVB Leerink	Reiterated Rating	Outperform	$45.00	N/A	i Rating by Michael Schmidt at SVB Leerink LLC
9/9/2016	BTIG Research	Reiterated Rating	Sell	$23.00	N/A	i
8/30/2016	BTIG Research	Initiated Coverage	Sell	$23.00	N/A	i
8/25/2016	Standpoint Research	Initiated Coverage	Buy	$47.00	N/A	i
8/5/2016	(FBRC)	Set Price Target	Buy	$61.00	N/A	i Rating by Edward White at (FBRC)
8/5/2016	Maxim Group	Lower Price Target	Buy	$80.00 ➝ $50.00	N/A	i Rating by Jason McCarthy at Maxim Group
7/18/2016	Maxim Group	Reiterated Rating	Buy	$80.00	N/A	i Rating by Jason McCarthy at Maxim Group
7/14/2016	SVB Leerink	Reiterated Rating	Buy	$86.00	N/A	i
7/10/2016	Maxim Group	Reiterated Rating	Buy	$80.00	N/A	i Rating by Jason McCarthy at Maxim Group
7/10/2016	Cowen	Reiterated Rating	Buy	$55.00	N/A	i
7/9/2016	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by Edward White at (FBRC)
7/8/2016	SVB Leerink	Reiterated Rating	Outperform	$60.00	N/A	i
7/8/2016	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$63.00 ➝ $39.00	N/A	i
7/8/2016	(FBRC)	Lower Price Target	Outperform	$73.00 ➝ $61.00	N/A	i Rating by Edward White at (FBRC)
7/6/2016	Barclays	Initiated Coverage	Equal Weight	$48.00	N/A	i
6/6/2016	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by Edward White at (FBRC)
6/2/2016	Raymond James	Initiated Coverage	Outperform	$52.00	N/A	i

(Data available from 5/16/2016 forward)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Today's Range

Now: $86.96

$86.96

50 Day Range

MA: $86.96

$86.96

52 Week Range

Now: $86.96

$19.62

$87.01

Volume

2 shs

Average Volume

5,484,542 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of 1877?

The following equities research analysts have issued stock ratings on 1877 in the last twelve months:
View the latest analyst ratings for JUNO.

What is the current price target for 1877?

0 Wall Street analysts have set twelve-month price targets for 1877 in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for 1877 in the next year.
View the latest price targets for JUNO.

What is the current consensus analyst rating for 1877?

1877 currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for JUNO.

How do I contact 1877's investor relations team?

1877's physical mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The biopharmaceutical company's listed phone number is +1-206-5821600. The official website for 1877 is www.junotherapeutics.com.